Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂，为预防绝经后骨质疏松症药物。
Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.
苯卓昔芬是一种选择性雌激素受体调节剂，为预防绝经后骨质疏松症药物。
声明：
上
、词性分类均由互联网资源自动生成，部分未经过人工审核，其
达内容亦
本软件的观点；若发现问题，欢迎向我们指正。
